Vadadustat: First Approval

<p><b>Declarations</b></p> <p><b><i>Funding</i></b> The preparation of this review was not supported by any external funding.</p><p><br></p> <p><b><i>Authorship and Conflict of interest</i></b> A. Markham is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.</p> <p> </p> <p> </p> <p></p><p><b><i>Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability </i></b>not applicable<b></b></p><p><br></p><p>Additional information about this Adis Drug Review can be found <b><a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews">here</a></b><br></p><p><br></p><p>Abstract</p><p><br></p><p></p><p>Vadadustat (VAFSEO^®) is a prolyl hydroxylase inhibitor being developed by Akebia Therapeutics, Inc. (Akebia) for the treatment of anaemia associated with chronic kidney disease (CKD). Akebia is collaborating with Mitsubishi Tanabe Pharma Corporation on the development and commercialization of vadadustat in Japan and with Otsuka Pharmaceutical Co. Ltd on the development and commercialization of vadadustat in the USA, the EU and certain other territories. The drug is approved in Japan for use in adult patients with anaemia associated with CKD and regulatory submissions are planned in the USA and the EU. This article summarizes the milestones in the development of vadadustat leading to this first approval.</p><p><br></p><p>© Springer Nature Switzerland AG 2020<br></p><br><p></p><p></p>